Table 4a):
Treatment of follow-up patients with C3 Glomerulopathy, with no MIg
| Treatment and follow-up labs | C3GN (n=70) |
DDD (n=8) |
|---|---|---|
| Duration of follow-up | Median: 22.3 months Range: 0.1–201.1 |
Median: 21.1 months Range: 0.2– 125.2 |
| Conservative management only | 31 (44.3%) | 3 (37.5%) |
| Therapeutic plasma exchange | 3 (4.3%) | 1 (12.5%) |
| Immunosuppressive therapy | 38 (54.3%) -Steroids only: 12 -Other immunosuppressive drugs with/without steroids: 26a(21 Mycophenolate Mofetil, 6 Eculizumab, 7Calcineurin inhibitors, 2 Rituximab, 3 Azathioprine, 4 Cyclophosphamide) |
4 (50%) -Steroid only: 0 -Other Immunosuppressive with/without steroids: 4a(3 Mycophenolate Mofetil, 1 Cyclophosphamide, 1 Eculizumab) |
| ACE-I/ARB | 52 (74.3%) | 8 (100%) |
| ESRD | 7 (10%)b | 2 (25%)b |
| Kidney transplant | 5 (7.1%) | 1 (12.5%) |
| Recurrent C3G post-transplant | 1 | 1 |
| Serum Creatinine (mg/dL) | Median: 1.5 (n=58) Range: 0.4–3.7 | Median: 0.7, (n=6) Range: 0.3–1.7 |
| Proteinuria (mg/24 hours) | Median: 904 (n=47) Range: 76–22,603 |
Median: 472 (n=5) Range: 101–1500 |
Abbreviations: ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; MIg, monoclonal Ig; NA; not available,
a
More than one immunosuppressive drug was given,
b
One patient presented with ESRD at diagnosis